{"id":1000,"date":"2016-08-18T16:33:24","date_gmt":"2016-08-18T11:03:24","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1000"},"modified":"2021-07-24T12:56:30","modified_gmt":"2021-07-24T07:26:30","slug":"notizia-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-2","title":{"rendered":"Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Branded product portfolio of Shionogi acquired by Lupin<br \/>\n<\/strong>Pharma giant <strong>Lupin<\/strong> entered into a strategic agreement when its Japanese subsidiary <strong>Kyowa Pharmaceutical Industry Co<\/strong>. purchased the product portfolio of Japan\u2019s <strong>Shionogi &amp; Co., Ltd<\/strong>. The agreement results in acquisition of 21 products long-listed, and the deal is said to become effective from December 1, 2016.<\/p>\n<p style=\"text-align: justify;\"><strong>FDA grants approval to Sanofi\u2019s Adlyxin<br \/>\n<\/strong>FDA reviewed results of GetGoal clinical program as well as the outcome of the ELIXA trial of French Company, <strong>Sanofi<\/strong>, and granted approval for Adlyxin drug. It is a one-time meal injection as an adjunct therapy to diet and exercise of T2D patients. The GetGoal program included 13 clinical trials involving over 5000 patients with T2D, for evaluating the safety and efficacy of lixisenatide (Adlyxin). The marketed drug will be available in pre-filled pen (disposable) with a single dose of 20 \u00b5g.<\/p>\n<p style=\"text-align: justify;\"><strong>NATCO gets approval for developing generic TAMIFLU by FDA<br \/>\n<\/strong><strong>NATCO<\/strong> and <strong>Alvogen<\/strong> became the first players to receive and approval for TAMIFLU through Para IV ANDA.\u00a0 TAMIFLU is the trade name for <strong>Roche\u2019s<\/strong> Oseltamivir Phosphate, and the companies have received approval for marketing generic of TAMIFLU oral capsules. This came after the companies settled a patent infringement with <strong>Gilead Lifesciences<\/strong>,<strong> Hoffmann-La Roche <\/strong>and<strong> Genentech Inc<\/strong>. The settlement agreement includes the right for <strong>NATCO\u2019s<\/strong> partner <strong>Alvogen<\/strong> to market the oseltamivir phosphate capsules before the expiration of the pediatric exclusivity period on February 23, 2017.<\/p>\n<p style=\"text-align: justify;\"><strong>FDA approves generic Glumetza from Sun Pharma<br \/>\n<\/strong><strong>Sun Pharma<\/strong>\u00a0(and its subsidiaries or associate companies) announced that one of <strong>Sun Pharma\u2019s <\/strong>subsidiary received a final approval from USFDA for ANDA for generic version of Glumetza that is Metformin Hydrochloride extended release tablets (500 mg and 1000 mg). These extended release tablets are the therapeutic equivalents of <strong>Santarus Inc.\u2019s <\/strong>Glumetza tablets.<\/p>\n<p style=\"text-align: justify;\"><strong>Ankleshwar unit of Wockhardt Ltd. gets an import alert from USFDA<br \/>\n<\/strong>An FDA inspection carried out in November, 2015 uncovered serious violations of GMP, leading to <strong>Wockhardt <\/strong>receiving an import alert for its Ankleshwar. This is the third plant of the company that has received an import alert. This has negatively impacted the company\u2019s plans to revive its business in the US market. The company saw US sales decline to 22% from the 24% of last year, mainly due to import restrictions. The Ankleshwar plant contributes 10-15 percent of the US sales (Rs 964 crore in FY16).<\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><strong>Patent fight of CRISPR: The bills hare soaring high<br \/>\n<\/strong>Fight over key patents on CRISPR genome editing has sent the legal bills soaring high, with the amount spent on the latest 10-Q filing from <strong>Editas Medicine<\/strong> to the <strong>Security and Exchange Commission<\/strong> touching the 10 million mark. The company reportedly paid $10.9 million as legal fees this past year to defend patents that have been awarded for CRISPR inventions by <strong>Broad\u2019s Feng Zhang<\/strong>. This cost is an addition to the $4.7 million already spent in 2015 for the same dispute. The most surprising fact is that the legal battle is far from being over, with the tussle set for many more years to come. This has certainly raised eyebrows everywhere.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Branded product portfolio of Shionogi acquired by Lupin Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product portfolio of Japan\u2019s Shionogi &amp; Co., Ltd. The agreement results in acquisition of 21 products long-listed, and the deal is said to become effective from December 1, 2016. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":941,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17274,647,17276,704,1135,794,17273,17275,524,533,17277,802,2499,595,17272],"industry":[17225],"therapeutic_areas":[17240,17228,17278],"class_list":["post-1000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adlyxin","tag-crispr","tag-editas-medicine","tag-fda","tag-genentech","tag-gilead","tag-lupin","tag-natco","tag-roche","tag-sanofi","tag-santarus","tag-sun-pharma","tag-tamiflu","tag-usfda","tag-wockhardt","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lupin acquired; FDA grants; NATCO gets approval; Wockhardt gets alert<\/title>\n<meta name=\"description\" content=\"Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupin acquired; FDA grants; NATCO gets approval; Wockhardt gets alert\" \/>\n<meta property=\"og:description\" content=\"Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-18T11:03:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lupin acquired; FDA grants; NATCO gets approval; Wockhardt gets alert","description":"Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-2","og_locale":"en_US","og_type":"article","og_title":"Lupin acquired; FDA grants; NATCO gets approval; Wockhardt gets alert","og_description":"Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-08-18T11:03:24+00:00","article_modified_time":"2021-07-24T07:26:30+00:00","og_image":[{"width":1440,"height":576,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-2","url":"https:\/\/www.delveinsight.com\/blog\/notizia-2","name":"Lupin acquired; FDA grants; NATCO gets approval; Wockhardt gets alert","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","datePublished":"2016-08-18T11:03:24+00:00","dateModified":"2021-07-24T07:26:30+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner.jpg","width":1440,"height":576},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021626\/news-banner-300x120.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adlyxin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Editas Medicine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NATCO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Santarus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sun Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tamiflu<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USFDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Wockhardt<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adlyxin<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">Editas Medicine<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Lupin<\/span>","<span class=\"advgb-post-tax-term\">NATCO<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Santarus<\/span>","<span class=\"advgb-post-tax-term\">Sun Pharma<\/span>","<span class=\"advgb-post-tax-term\">Tamiflu<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>","<span class=\"advgb-post-tax-term\">Wockhardt<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 18, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 18, 2016 4:33 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1000"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1000\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/941"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1000"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1000"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}